Navigation Links
Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis

HAE:TSX

MONTREAL, June 14, 2007 /PRNewswire-FirstCall/ Haemacure Corporation , a Montreal-based specialty biotherapeutics company, today announced the preliminary findings of the content analysis of one of its plasma discards.

Preliminary findings confirm the presence of a number of proteins and enzymes with applications in significant worldwide markets, including albumin, plasminogen, immunoglobulin and A1PI.

These findings take on a strategic significance for Haemacure as revenues eventually generated from the commercial exploitation of these proteins and enzymes will constitute a direct contribution to the bottom line. This is because the cost of the plasma will be fully borne by Haemacure's fibrin sealant and hemostatic agent once these products will be commercialized.

"We are very excited with the positive outcome of the content analysis of one of our plasma discards," said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "This is the first tangible result of our new biotherapeutics orientation that we announced at our recent meeting of shareholders. The identification of these proteins and enzymes indicates that our patented plasma protein extraction technology yields significant potential benefits superior to the traditional extraction technology. With these results in hand, and further to interest expressed by third parties in our plasma discard, we will drive towards implementing our business development strategy that encompasses partnerships with pharmaceutical and biotechnology companies." concluded Mr. Galli.

Haemacure plans on harvesting albumin from this discard and using it in the production of its fibrin sealant, representing annual cost savings estimated at more than US$500,000 at full production plant capacity. Some albumin extracted could also be available for commercialization.

According to the Marketing Research Bureau, the world pla
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/4/2015)... 4, 2015 Southfield Capital, a ... announced today that it completed a dividend ... specializes in the development and multi-channel deployment ... and biotechnology industries. Through the ... half of their invested capital and secured ...
(Date:5/4/2015)... 2015 PharmaEngine, Inc. (TWO:4162) today announced ... MACK ) with its sublicensing partner, Baxter ... that Baxter has submitted a marketing authorization application ... MM-398 (irinotecan liposome injection), also known as "nal-IRI," ... who have been previously treated with gemcitabine-based therapy. ...
(Date:5/4/2015)... 2015  By looking at the brain, scientists ... two very different conditions that can have very ... MD, PhD., a Denver -based ... study can help the medical community better ... for Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain ...
Breaking Medicine Technology:Southfield Capital and BioPharm Communications Announce Dividend Recapitalization 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3
... PORTLAND, Oregon, Nov. 8, 2010 A leading Internet ... There are ways to get affordable medicines without using ... LegitScript, a firm that monitors "rogue" Internet pharmacies and ... allowing Internet users who cannot afford their medicines ...
... 2010 Shrink Nanotechnologies, Inc. ("Shrink") (OTC Bulletin ... company developing products and licensing opportunities in the ... biotechnology research and development tools businesses, revealed working ... StemDisc450™, a high-yield, low cost, patent-pending cell culturing ...
Cached Medicine Technology:Need Help Affording Your Meds? LegitScript Adds Patient Assistance Feature 2Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 2Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 3Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 4Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells 5
(Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
(Date:5/4/2015)... 2015 The American Telemedicine Association (ATA) ... reports which identify gaps in coverage and reimbursement, and ... the State Telemedicine Gaps Reports last September, many state ... and regulations impact healthcare delivery in their state,” said ... state actions across the nation, ATA reevaluated the indicators ...
(Date:5/4/2015)... May 04, 2015 In May of 2010, ... his own life. In the wake of this tragedy, Ty’s ... an organization that exposes the grim reality of bullying and ... platform for Kirk and Laura to share their story and ... from happening to another family — a mission that took ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Now in ... IPC clinical leaders who have made outstanding contributions to ... they serve, both in acute and post-acute care settings. ... Year, Post-Acute Provider of the Year, Advanced Practice Clinician ... Specialist Provider of the Year. Recipients are selected by ...
(Date:5/4/2015)... 04, 2015 EyeCRO LLC and NeuMedics ... facilitate development of NM108, a first-in-class small molecule to ... blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics ... EyeCRO, which can deliver drugs to the front and ... , Under the terms of the agreement, EyeCRO will ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3
... BETHESDA, Md., July 31 Hanger Orthopedic Group, Inc. (NYSE: ... raised its rating on Hanger Orthopedic Group, Inc. to "B1" from ... senior secured debt to "Ba2" from "Ba3" and senior unsecured debt ... "Stable" outlook. , , "We are extremely pleased ...
... , , ... Administration today approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension ... It is the first once-monthly, long-acting, injectable atypical antipsychotic approved ... Pharmaceuticals, Inc, will market INVEGA SUSTENNA in the U.S. , ...
... , , , CARLSBAD, ... company developing targeted therapeutics for the treatment of skin scarring ... Birnbaum, Ph.D. has joined the Board of Directors as an ... Birnbaum is a dermatology consultant specializing in ethical and OTC ...
... are found to have more health and social issues years ... of the childhood cancer neuroblastoma face long-term health and social ... data on 954 people who had been diagnosed with neuroblastoma ... between 1970 and 1986, comparing it with data on 3,899 ...
... procedures, survey shows , FRIDAY, July 31 (HealthDay News) -- ... visited a plastic surgeon for a "makeover" -- a ... around her lips and at the corners of her mouth. ... might lose her competitive edge in a tightening job market. ...
... , WASHINGTON, July 31 The following is ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ... an important step to protect the District,s kids and taxpayers from the ... cents to $2.50 per pack - the seventh highest cigarette tax in ...
Cached Medicine News:Health News:Hanger Orthopedic Group, Inc. Receives Upgrade From Moody's Investors Service 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9Health News:Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors. 2Health News:Plastic Surgeons Stay Busy in Recession 2Health News:Plastic Surgeons Stay Busy in Recession 3Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: